Delivery Order SPE2DB22D1017-SPE2DB25FG3VY
- Not listed
- The Defense Logistics Agency awarded a $25,827.06 delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Eliquis 5 mg tablets in quantities of 60 per package. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 13, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary headquarters and...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Eliquis 5 mg tablets (60-count packages) with a ceiling value of $18,978.90. This non-set-aside competitive award is scheduled for completion by August 8, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction under the company's...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $8,311.84 by the Defense Logistics Agency (DLA) on April 30, 2025, for the supply of Eliquis 5 mg tablets (60-count units). The contract, which is not set-aside, utilizes firm fixed pricing and carries an ultimate completion date of May 1, 2025. Performance of this order is based in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under a larger Indefinite...
- The Defense Logistics Agency awarded a $14,034.53 delivery order to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count units) on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Eliquis 5 mg tablets (60-count units) valued at $13,624.62 on April 10, 2025, with completion scheduled for April 11, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 and extending through December 2026....
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $13,726.08 on August 27, 2025, for the supply of Eliquis 5 mg tablets (60-count units). This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 28, 2025. The product will be delivered to Conshohocken, Pennsylvania, AmerisourceBergen's corporate headquarters location. This delivery order represents a child contract executed under...
- The Defense Logistics Agency awarded a delivery order valued at $8,887.80 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count) on September 2, 2025, with an ultimate completion date of September 3, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $5,117.59 for 60 tablets of Eliquis 5 mg on August 13, 2025, with an ultimate completion date of August 14, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and specifies Conshohocken, Pennsylvania as the place of performance, which is AmerisourceBergen's corporate headquarters. The delivery order is issued under the company's larger Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Eliquis 5 mg tablets (60-count units) at a firm fixed price ceiling value of $25,069.77. This non-set-aside, competitively awarded contract is scheduled for completion by August 15, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count packages) valued at $16,636.35 under a firm fixed-price contract. The award was made on August 25, 2025, with an ultimate completion date of August 26, 2025, and represents a non-set-aside competitive procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the delivery of this pharmaceutical product from its corporate office...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FG3VYDelivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $7,846.57 for Eliquis 5 mg tablets (60-count) on May 30, 2025, with an ultimate completion date of June 2, 2025. This firm fixed price, non-set-aside contract represents a direct purchase under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to the company's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and primary distribution operations. This delivery order is executed under AmerisourceBergen's comprehensive pharmaceutical prime vendor agreement (SPE2DX) valued at $999,999,999.00 through December 2026, which serves as a global supply vehicle for military healthcare programs. Eliquis, an anticoagulant medication, supports the broader Defense Health Agency mission of maintaining pharmaceutical supply chains for military personnel and veterans. AmerisourceBergen's role as a primary pharmaceutical distributor for DLA reflects its established capability to meet federal procurement requirements through competitive processes and deliver critical medications across multiple therapeutic domains to support defense healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.8k | 5/30/25 |